About 5 results found for searched term "OK-101" (0.125 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M45240 | OK-101 | Others |
| OK-101 is a lipid-coupled chemokine peptide agonist of the ChemR23 g-protein-coupled receptor that can be used in studies related to neuropathic corneal pain (NCP). | ||
| M15043 | Recombinant Human Adiponectin/Acrp30 (HEK 293) | Cytokines and Growth Factors |
| Acrp-30; GBP-28; Apm-1 | ||
| Adiponectin is an important adipocytokine involved in the control of fat metabolism and insulin sensitivity. It is made only by fat cells and secreted into plasma. Protein structure: Acrp30 (Lys101-ASN244), Accession # ：Q15848. | ||
| M15024 | Recombinant Human MIP-1α/CCL3 (CHO) | Cytokines and Growth Factors |
| Macrophage Inflammatory Protein-1α; CCL-3; LD78α; LD78 alpha | ||
| Mip-1 Alpha, also known as CCL3, G0S19-1 and SCYA3, LD78 Alpha, is an inflammatory chemokine. Mip-1 α belongs to the CCL chemokine family and has 68% homology with MIP-1β. The mature form of MIP-1α contains 69 amino acids, which are present in solution as dimers and tend to accumulate reversibly. Protein structure: MIP-1α (ALA27-ALA92), Accession # : P10147. | ||
| M15035 | Recombinant Human IL-8/CXCL8 (77aa, CHO) | Cytokines and Growth Factors |
| IL8; CXCL8; monocyte-derived neutrophil chemotactic factor | ||
| Interleukin-8 (IL-8), also known as CXCL8, GCP-1 and NAP-1, is one of the first discovered chemokines and belongs to the CXCL family, in which the first two conserved cysteines are separated by one residue. Protein Construction: IL-8 (Ala23-Ser99). Accession # P10145. | ||
| M15053 | Recombinant Mouse CCL2/MCP-1 (E.coli) | Cytokines and Growth Factors |
| C-C motif chemokine 2; Monocyte chemoattractant protein 1 | ||
| Recombinant mouse C-C Motif Chemokine 2, produced by escherichia coli expression system, expressed the target gene encoding GLN24-ARG96. Accession # : P10148. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
